MANAGEMENT OF CUTANEOUS ADVERSE EFFECTS DURING TREATMENT WITH ZD1839 AS THIRD- OR FOURTH-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SURPRISING EFFICACY OF EARLY LOCAL TREATMENT


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles